While new immunosuppressive agents have primarily reduced the incidence of acute rejection episodes, thereby reducing early morbidity and costs, chronic processes remain a major cause of graft loss [1,2]. Among the multiple factors that determine the interactions between host and graft, optimization of the immunosuppressive regimen is potentially the most modifiable and thus important factor in preventing the progression of rejection processes that determine graft
survival...

Keywords: Pharmacokinetics, cyclosporin, pharmacodynamics, Tacrolimus, Sirolimus